Skip to main content
Settings
Color Mode
Theme Skin
Background

Appearance preferences are saved in this browser only.

Environment
Current Environment Production

Built with JEKYLL_ENV=production. Changes require deployment.

Quick Links
Theme & Build
Theme
Jekyll v3.10.0
Last Build Oct 03, 21:40
Repository
ai-world-view/south-korea
Changelog Docs Jekyll
Page Info
Layout default
Collection none
Path economy/pharmaceutical-biotech-industry.md
URL /economy/pharmaceutical-biotech-industry/
Date 2026-08-27
Source Code

Set repository: USER/REPO in your _config.yml to enable source-code shortcuts.

Pharmaceutical and Biotech Industry — Advanced Manufacturing and the Life-Sciences Pivot

South Korea’s pharmaceutical and biotechnology industry has emerged as a significant and rapidly growing sector within the country’s advanced-manufacturing and innovation ecosystem. Historically, the Korean pharmaceutical market was dominated by generic and over-the-counter medicines and contract manufacturing for international companies, but since the 2000s, the sector has undergone a deliberate transformation toward innovation-driven biopharmaceuticals, proprietary novel compounds, and position as a global contract manufacturing hub. By 2023, South Korea’s pharmaceutical exports exceeded $15 billion, and the country ranked among the top ten pharmaceutical-producing nations globally. The industry now combines large integrated pharmaceutical companies, specialized biotech firms, contract research and manufacturing organizations (CROs/CMOs), and a growing venture-capital ecosystem focused on life sciences.

Historical Development and Traditional Pharma

Colonial and Post-war Era

Korea’s modern pharmaceutical industry emerged during the Japanese colonial period (1910–1945) and expanded significantly after liberation. Early companies were primarily importers and distributors of Western medicines; domestic manufacturing capacity was minimal. The Korean War (1950–1953) disrupted what limited pharmaceutical production existed, but post-war reconstruction created intense demand for medicines, antibiotics, and vaccines, prompting the establishment of Korea’s first domestically owned manufacturing plants.

Growth Era (1960s–1990s)

During Park Chung-hee’s developmental-state period, the pharmaceutical sector was identified as a strategic component of the chemical and fine-chemicals complex. The government encouraged local pharmaceutical manufacturing through tariff protection, import licensing, and preferential access to credit. Major companies established or expanded during this era include:

  • Dong-A Pharmaceutical (동아제약, founded 1932 and reorganized post-war) — Korea’s oldest major pharmaceutical firm, producing a broad range of branded and generic medications.
  • Yuhan Corporation (유한양행, founded 1926 by Ryu Il-han) — One of Korea’s most storied pharmaceutical companies, known for maintaining unusually transparent governance and employee stock ownership.
  • Cheil Pharmaceutical (제일제약, founded 1954) — A major producer that later became part of Samsung’s diversification into pharmaceuticals.
  • Boryung Pharmaceutical (보령제약, founded 1960) — Best known domestically for Carobis (a bestselling antacid) and cardiovascular medicines.
  • Hanmi Pharmaceutical (한미약품, founded 1973) — Would become one of Korea’s most globally prominent mid-size innovators.

These companies focused on manufacturing antibiotics, painkillers, vitamins, OTC cold and digestive remedies, and licensed manufacturing of foreign-patented drugs. The industry was highly fragmented — at its peak in the 1980s there were more than 300 licensed pharmaceutical manufacturers in Korea — and the domestic regulatory environment, while nominally supervised by the Ministry of Health, was looser than contemporary standards.

The 1990s: Crisis and the Seeds of Transformation

The 1997 Asian Financial Crisis (IMF crisis) created significant disruption. Many smaller pharmaceutical firms were acquired or failed. Samsung’s pharmaceutical division, LG Chem’s pharma arm, and SK Pharma (part of SK Group) consolidated positions within the chaebol structure. More significantly, the crisis forced strategic reflection: Korean companies recognized they could not compete on volume with Indian and Chinese generic manufacturers and had to move up the value chain toward biopharmaceuticals and novel drug discovery.

Modern Transformation (2000s–Present)

The Biotech Pivot and Government Policy

Beginning in the early 2000s, the government launched a series of biotech development initiatives under what became known as the Bio-Industry Development Plan (바이오산업 발전전략):

  • R&D tax credits of up to 30% for pharmaceutical companies’ research expenditure (higher rates for small and medium firms).
  • National Health Technology R&D Program (국가 건강기술연구개발사업), channeling hundreds of billions of won annually into life-sciences research at universities, hospitals, and national research institutes.
  • Bio-Cluster development — deliberate geographic concentration of pharma R&D in specific zones, most notably the Songdo Global Bio Cluster (송도 글로벌 바이오 클러스터) in Incheon Free Economic Zone, which became the primary location for Korea’s largest biopharmaceutical manufacturing facilities.
  • Korea Drug Development Fund (KDDF, 범부처신약개발사업단) — a public-private partnership co-funding early clinical development of Korean-origin drug candidates.

The identification of biotechnology alongside semiconductors and digital media as a “next-generation growth engine” (차세대 성장 동력) gave the industry political priority and sustained funding through multiple administrations.

Major Companies and Segments

Large Integrated Pharmaceuticals:

  • Yuhan Corporation (유한양행) — In 2018 Yuhan and Janssen (Johnson & Johnson) announced a landmark licensing deal for Lazertinib, a third-generation EGFR-mutant non-small-cell lung-cancer drug, in a deal potentially worth over $1.25 billion, validating Korean pharma’s capacity for original innovative medicine. A subsequent partnership with Johnson & Johnson led to global Phase III trials.
  • Hanmi Pharmaceutical (한미약품) — In September 2015, Hanmi announced licensing agreements totaling approximately $5.3 billion in potential milestone payments with Sanofi (for a GLP-1/glucagon dual agonist), Eli Lilly, Boehringer Ingelheim, and others — the largest pharmaceutical licensing deals in Korean history at the time, though some were later restructured after clinical setbacks. Hanmi’s HM12525A (efpeglenatide, a GLP-1 receptor agonist) advanced into Phase III trials. The episode demonstrated that Korean pharma had developed genuine pipeline assets valuable to global majors.
  • Dong-A ST (동아에스티, the specialty pharmaceutical arm of Dong-A) — Focuses on original drug development including Ticagrelor-based cardiovascular medicines and export of injectable products.

The Samsung Life-Sciences Ecosystem:

Samsung’s investment in biopharmaceuticals has been the most dramatic example of chaebol diversification into the sector:

  • Samsung Biologics (삼성바이오로직스, founded 2011) — A dedicated contract development and manufacturing organization (CDMO) based in Incheon’s Songdo. By 2024, Samsung Biologics had become the world’s largest biopharmaceutical CDMO by production capacity, with four manufacturing plants totaling over 600,000 liters of bioreactor capacity — surpassing Lonza and other traditional Western CDMOs. Samsung Biologics is listed on the KOSPI and produces monoclonal antibodies and other biologic drugs for dozens of global pharmaceutical companies under contract.
  • Samsung Bioepis (삼성바이오에피스, founded 2012) — A 50/50 joint venture between Samsung Biologics and Biogen (US), specializing in biosimilar development. Samsung Bioepis has become one of the world’s most successful biosimilar companies, with approved products including:
    • Renflexis (infliximab, biosimilar to Remicade) — approved by FDA and EMA.
    • Hadlima (adalimumab, biosimilar to Humira) — approved in the US and Europe.
    • Ontruzant (trastuzumab, biosimilar to Herceptin) — approved in the US and Europe.
    • Byooviz (ranibizumab, biosimilar to Lucentis) — approved in the US. In 2022, Biogen sold its 49.9% stake in Samsung Bioepis back to Samsung Biologics for approximately $2.3 billion, making Samsung Bioepis a wholly-owned Samsung subsidiary.

Celltrion (셀트리온):

Founded in 2002 by Seo Jung-jin (서정진) — a former Daewoo Motor executive — Celltrion is South Korea’s most internationally prominent independent biopharmaceutical company. Operating from Incheon’s Songdo district, Celltrion’s pivotal achievement was developing CT-P13 (Remsima/Inflectra), an infliximab biosimilar (biosimilar to Janssen’s Remicade). In September 2013, CT-P13 became the first monoclonal antibody biosimilar approved by the European Medicines Agency (EMA) — a landmark for the global biosimilar industry. CT-P13 was subsequently approved by the FDA in 2016. Celltrion has since expanded its pipeline to include:

  • CT-P10 (rituximab biosimilar, Truxima) — approved EMA and FDA.
  • CT-P6 (trastuzumab biosimilar, Herzuma) — approved EMA and FDA.
  • CT-P17 (adalimumab high-concentration biosimilar, Yuflyma) — approved EMA and FDA.
  • CT-P59 (regdanvimab) — a COVID-19 monoclonal antibody treatment developed and approved in South Korea in 2021.

Celltrion is publicly listed on the KOSPI and had a market capitalization of approximately $20 billion as of 2023. Seo Jung-jin briefly retired from the CEO role in 2021 but returned amid governance disputes; the company merged Celltrion Healthcare (its domestic and international sales arm) with the parent Celltrion in a consolidation completed in 2023.

SK Bioscience (SK바이오사이언스):

SK Bioscience, a subsidiary of SK Group, became internationally prominent during the COVID-19 pandemic. The company manufactured the AstraZeneca-Oxford vaccine (ChAdOx1, Vaxzevria) under contract for South Korea and global supply, producing hundreds of millions of doses from its Andong facility in North Gyeongsang Province. SK Bioscience also developed its own COVID-19 vaccine, SKYCovione (GBP510), which used a protein subunit platform co-developed with the University of Washington’s Institute for Protein Design; it received Korean MFDS approval in June 2022, making it one of the few fully domestically developed COVID-19 vaccines among major economies. The episode underscored the importance of domestic vaccine manufacturing capacity, and the government invested substantially in expanding Korean vaccine production infrastructure as part of K-Bio Health Security initiatives.

Mid-size Specialty and Biotech Firms:

  • Medytox (메디톡스) — Korea’s leading producer of botulinum toxin products (cosmetic neurotoxin, therapeutic indications), with products approved in South Korea, Asia, and internationally under the Meditoxin brand. Medytox became embroiled in a complex patent dispute with Hugel and Daewoong Pharmaceutical over the bacterial strain used for botulinum toxin fermentation — a case that drew global attention to Korea’s competitive biotech IP environment.
  • Hugel (휴젤) — A competing botulinum toxin manufacturer that successfully listed on KOSDAQ and expanded exports globally; also produces medical aesthetics products. In 2021 Hugel received US FDA approval for Letybo (letibotulinumtoxinA) for glabellar lines, becoming the first Korean botulinum toxin product approved in the US.
  • Genexine (제넥신) — Focused on immunotherapy, therapeutic vaccines, and long-acting biologics using the HyFc technology platform.
  • OliX Pharmaceuticals (올릭스) — Developing asymmetric siRNA (RNA interference) therapeutics for fibrotic diseases, scarring, and metabolic conditions; an example of Korea’s expanding presence in RNA-based therapeutics.
  • Boryung (보령제약) — Traditional large pharma that has expanded internationally, including acquiring Dainippon Sumitomo’s CNS pipeline assets.

Contract Research and Manufacturing (CROs/CMOs):

Beyond Samsung Biologics, Korea has developed a significant CRO/CMO ecosystem:

  • Samsung Biologics (as above) — the world’s largest biologic CDMO by capacity.
  • Celltrion (as above) — has CMO operations alongside proprietary pipeline.
  • Daewoong Pharmaceutical (대웅제약) — major generics and growing CMO.
  • Binex (바이넥스) — A mid-size CDMO specializing in cell and gene therapy manufacturing.
  • Korea’s lower manufacturing costs relative to Japan and the US, high technical skill, and regulatory recognition have made it an attractive CMO destination for global companies seeking to diversify from European and North American manufacturing.

Key Therapeutic Areas

Korean biotech has concentrated in several therapeutic domains:

  • Biosimilars — Particularly monoclonal antibodies for inflammatory diseases (infliximab, adalimumab, etanercept), cancers (trastuzumab, rituximab, bevacizumab), and ophthalmology (ranibizumab). Celltrion and Samsung Bioepis have been world leaders.
  • Metabolic diseases — GLP-1 receptor agonists and dual/triple agonists for diabetes and obesity (Hanmi’s pipeline). Korea’s growing obesity rate has also made domestic clinical trials in metabolic disease more feasible.
  • Oncology — Targeted small-molecule and biologic therapies. EGFR inhibitors for lung cancer have been a particular area of strength, given the high incidence of EGFR-mutant lung cancer in the Korean and broader East Asian population.
  • Medical aesthetics and neurotoxins — Botulinum toxin products (Medytox, Hugel, Daewoong’s Nabota, which became the first Korean BoNT product approved by FDA in 2019).
  • RNA therapeutics — Growing presence in siRNA and mRNA platforms, accelerated by COVID-19 pandemic-era investment.
  • Cell and gene therapy — Early-stage but growing; several academic-spinout companies working on CAR-T and stem-cell approaches.

Research Infrastructure and Talent

Biotech Clusters

The Songdo Global Bio Cluster (송도 글로벌 바이오 클러스터, Incheon) is the most concentrated life-sciences manufacturing zone, housing Samsung Biologics, Celltrion, and dozens of affiliated research and manufacturing organizations. The cluster was developed as part of the Incheon Free Economic Zone, which offered foreign-owned companies and joint ventures regulatory streamlining and land subsidies.

Other clusters include:

  • Osong Health Technology Administrative City (오송) in North Chungcheong Province — home to the Korea Centers for Disease Control and Prevention (KDCA), National Institute of Health, and MFDS regulatory science centers.
  • Daejeon Daedeok Innopolis (대덕 연구개발특구) — Korea’s primary science R&D cluster, hosting KAIST, Korea Research Institute of Bioscience and Biotechnology (KRIBB), and numerous biotech spinouts.
  • Seoul National University (SNU) Medical Complex — a concentration of clinical research, pharmaceutical R&D, and hospital-based translational science.

Research Institutions

  • Korea Centers for Disease Control and Prevention (KDCA) — Coordinates national disease surveillance and supports vaccine and infectious-disease research.
  • Korea Research Institute of Bioscience and Biotechnology (KRIBB) — A government-funded institute conducting fundamental and applied life-sciences research.
  • National Institute of Health (NIH Korea, 국립보건연구원) — Under the KDCA, supports pharmaceutical and vaccine translational research.
  • KAIST (Korea Advanced Institute of Science and Technology) — Leading academic institution in bioengineering, synthetic biology, and pharmaceutically relevant chemistry.
  • POSTECH — Strong biochemistry and materials science programs with growing pharma-relevant research.

Talent Pipeline

Korea’s pharmaceutical and biotech sector benefits from a large pool of PhD-level scientists in molecular biology, biochemistry, pharmacology, and bioengineering produced annually by Korean universities. A distinctive feature has been the return of overseas-trained Korean scientists (한국계 과학자 귀국) from positions in the US, Europe, and Japan, bringing both technical expertise and international networks. The Korea Research Foundation and various government programs (Brain Korea 21) incentivize this return through salary supplements and research funding.

Regulatory Framework and Clinical Trials

South Korea’s Ministry of Food and Drug Safety (MFDS, 식품의약품안전처) — equivalent to the US FDA — oversees drug and biologic approval. Korea has aligned its regulatory framework with International Council for Harmonisation (ICH) standards, allowing Korean clinical trial data to be used directly in US and European regulatory submissions in most cases.

South Korea is a globally significant clinical trial hub:

  • By 2023, Korea was consistently ranked among the top 10 nations globally for clinical trial volume, with more than 900 ongoing trials registered with the MFDS at any given time.
  • Lower trial costs relative to the US and Europe, efficient patient recruitment through Korea’s universal health system and hospital network, and high trial-site quality have made Korea attractive to global sponsors.
  • Korea’s National Health Insurance (국민건강보험) system, which covers nearly all residents, provides researchers with access to large longitudinal health datasets useful for patient selection and outcomes research.
  • Clinical trial revenue contributed an estimated $1.5–2 billion annually to the Korean economy by the early 2020s.

Korea also has accelerated approval pathways for specific categories (orphan drugs, conditional approvals for unmet medical need) that parallel FDA and EMA Accelerated/Conditional Marketing Authorization programs.

Global Position and Exports

Korean pharmaceutical and biotech exports grew from under $2 billion in 2010 to more than $15 billion by 2023, driven primarily by:

  • Biosimilar and biologic drug exports to the US, Europe, and Asia-Pacific.
  • CDMO/CMO services — manufacturing services provided under contract to global pharmaceutical companies by Samsung Biologics, Celltrion, and others; counted as service exports.
  • Generic pharmaceutical exports to ASEAN, Middle East, and Africa.

Major export destinations include:

  • United States — Largest market for biosimilar products and CMO services.
  • European Union — Particularly Germany, France, and the UK for biosimilars.
  • ASEAN — Singapore, Vietnam, Indonesia for generic and branded pharmaceuticals.
  • Japan — Growing market for biosimilars and specialty drugs.

Korea’s pharmaceutical trade balance turned positive in approximately 2018 — a milestone given the sector’s decades-long dependency on imported APIs and finished drugs.

Challenges and Future Directions

Drug Pricing and Domestic Reimbursement

Korean pharmaceutical companies face intense pressure from domestic healthcare cost controls. The Health Insurance Review and Assessment Service (HIRA, 건강보험심사평가원) regulates drug pricing and reimbursement under the National Health Insurance framework, with a particular emphasis on cost-effectiveness. Drug prices in Korea are significantly lower than in the US, limiting the domestic profitability of innovative medicines. This structural challenge pushes Korean biotech toward international markets (especially the US) where pricing reflects innovation value, despite the additional regulatory and commercial complexity.

The government’s Pharmaceutical Price Reform policy (약가 일괄인하) periodically adjusts reference prices downward, creating cash-flow uncertainty for mid-size domestic manufacturers.

Patent Cliffs and Biosimilar Competition

The global “patent cliff” — the expiration of major biologic drug patents — has created both opportunity and intensifying competition. Korean biosimilar manufacturers have been leaders in this space, but competition from Indian, Chinese, and other producers (including Coherus Biosciences, Sandoz, and Pfizer in the US market) is increasing. Maintaining competitive manufacturing cost and regulatory credibility is ongoing work.

Venture Capital and Startup Ecosystem Maturation

Korea’s biotech startup ecosystem has expanded since the late 2010s, with dedicated life-sciences funds established by KDB (Korea Development Bank), KVIC (Korea Venture Investment Corporation), and global investors. However, the ecosystem still lacks the density of the US biotech clusters (Boston, San Francisco Bay Area), particularly for late-stage clinical development funding. Korean biotech founders increasingly seek dual listings on KOSDAQ and NASDAQ or partnerships with global pharma to access development capital. The KOSDAQ technology-sector listing rules include provisions for pre-revenue biotech companies, supporting early listing.

Regulatory and IP Environment

Korea’s pharmaceutical IP framework, particularly around data exclusivity and patent linkage (linking drug approval to patent status), has evolved under pressure from bilateral trade agreements (including the Korea-US FTA, KORUS). Strengthening IP protection has made Korea more attractive for innovative pharmaceutical companies while creating tensions with domestic generics manufacturers and cost-containment goals.

Cultural Dimensions and Traditional Medicine

South Korea maintains a dual healthcare system encompassing both Western (양의학) and Traditional Korean Medicine (한의학, hanuihak). Licensed hanuisa (한의사, traditional Korean medicine doctors) practice alongside Western-trained physicians under separate national boards. The pharmaceutical industry straddles both: several companies produce natural-product-derived or traditional-medicine-inspired formulations, including extracts of ginseng (인삼, a traditional Korean export commodity), angelica root, and other medicinal herbs, positioning them in both the domestic health-food and international nutraceutical markets.

The global success of Korean beauty (K-beauty) has created spillover interest in Korean cosmeceuticals — the boundary between cosmetics and pharmaceuticals in products like skin-whitening, anti-aging, and dermatological treatments. Companies like Amorepacific invest in clinically substantiated active ingredients, blurring the cosmetics-pharma line in a way regulators in various markets are still adjudicating.